Level Four Advisory Services LLC Reduces Stock Position in VanEck Pharmaceutical ETF $PPH

Level Four Advisory Services LLC decreased its position in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 59.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,031 shares of the company’s stock after selling 22,464 shares during the quarter. Level Four Advisory Services LLC’s holdings in VanEck Pharmaceutical ETF were worth $1,358,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Citigroup Inc. boosted its stake in shares of VanEck Pharmaceutical ETF by 987.8% during the 3rd quarter. Citigroup Inc. now owns 718,199 shares of the company’s stock worth $64,896,000 after purchasing an additional 652,175 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of VanEck Pharmaceutical ETF during the second quarter valued at approximately $28,587,000. J.Safra Asset Management Corp grew its stake in VanEck Pharmaceutical ETF by 4.4% in the 3rd quarter. J.Safra Asset Management Corp now owns 285,787 shares of the company’s stock worth $25,824,000 after acquiring an additional 12,011 shares during the period. JPMorgan Chase & Co. raised its holdings in VanEck Pharmaceutical ETF by 0.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 256,985 shares of the company’s stock valued at $23,221,000 after acquiring an additional 1,148 shares during the last quarter. Finally, Verity & Verity LLC acquired a new position in VanEck Pharmaceutical ETF in the 2nd quarter valued at $11,551,000.

VanEck Pharmaceutical ETF Stock Down 2.3%

Shares of VanEck Pharmaceutical ETF stock opened at $106.33 on Friday. VanEck Pharmaceutical ETF has a fifty-two week low of $77.67 and a fifty-two week high of $112.58. The firm has a market cap of $1.17 billion, a PE ratio of 20.21 and a beta of 0.54. The business’s fifty day moving average is $107.42 and its two-hundred day moving average is $98.78.

VanEck Pharmaceutical ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 29th were given a dividend of $0.3106 per share. The ex-dividend date was Monday, December 29th. This represents a $1.24 annualized dividend and a yield of 1.2%.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.